

**FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)
ANTI-INFECTIVE DRUGS ADVISORY COMMITTEE**

**DRAFT AGENDA
November 19, 2008 (Morning Session)**

The committee will discuss NDA 022-110 Telavancin, Theravance, Inc. and Astellas Pharma, Inc., proposed indication for the treatment of complicated skin and skin structure infections (cSSSI)..

8:00 am	Call to Order and Opening Remarks	Acting Chair, Anti-Infective Drugs Advisory Committee
	Introduction of Committee Conflict of Interest Statement	Janie Kim, PharmD Designated Federal Officer
8:15 am	Introduction/Background	TBD
9:00 am	Applicants presentation	Theravance
10:00 am	FDA Presentations	TBD
9:45 am	Questions/Clarification	
10:30 am	Break	
11:30 am	Open Public Hearing	
11:45 am	Charge and Questions to the Committee	
12:30 pm	Lunch	